海南双成药业股份有限公司 关于筹划重大资产重组停牌前一个交易日前十大股东和前十大 流通股股东持股情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 海南双成药业股份有限公司（以下简称"公司"）拟以发行股份及支付现金 的方式向 Hong Kong Aura Investment Co. Limited/香港奥拉投资有限公司、Win Aiming Limited/赢准有限公司等 25 名交易对方购买其持有的宁波奥拉半导体股 份有限公司 100%股份，并拟向不超过 35 名特定投资者发行股份募集配套资金。 证券代码：002693 证券简称：双成药业 公告编号：2024-063 1 | 序号 | 股东名称 | 持有数量（股） | 占公司总股本的 比例（%） | 股东类别 | | --- | --- | --- | --- | --- | | 6 | 陈文宜 | 2,453,900 | 0.59 | 境内自然人 | | 7 | 王成栋 | 2,110,906 | 0.51 | 境内自然人 | | 8 | 许尚龙 | 1,563,900 | 0.38 | 境内自 ...

证券代码：002693 证券简称：双成药业 公告编号：2024-059 海南双成药业股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 海南双成药业股份有限公司（以下简称"公司"或"上市公司"）第五届董 事会第十五次会议通知于 2024 年 9 月 7 日以书面送达或电子邮件等方式发出， 并于 2024 年 9 月 10 日 13:00 以现场结合通讯表决的方式召开。会议应出席董事 6 人，实际参加表决的董事 6 人。本次会议由董事长王成栋先生主持，会议的召 开符合有关法律法规、公司章程的规定。 二、董事会会议审议情况 （一）审议了《关于公司发行股份及支付现金购买资产并募集配套资金暨 关联交易符合相关法律法规之规定的议案》 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司重大资 产重组管理办法》《上市公司证券发行注册管理办法》等法律、法规、部门规章 及规范性文件规定，结合公司实际运营情况以及本次交易相关事项的自查、论证 情况，本次发行股份及支付现金购买资产并募集配套资金暨关联交易 ...

关于本次交易采取的保密措施及保密制度的说明 海南双成药业股份有限公司（以下简称"公司"）拟以发行股份及支付现金 的方式向 Hong Kong Aura Investment Co. Limited/香港奥拉投资有限公司、Win Aiming Limited/赢准有限公司等 25 名交易对方购买其持有的宁波奥拉半导体股 份有限公司 100%股份，并拟向不超过 35 名特定投资者发行股份募集配套资金 （以下简称"本次交易"）。 海南双成药业股份有限公司董事会 1、公司筹划本次交易期间高度重视内幕信息管理，公司与交易相关方就本 次交易进行初步磋商时，已经采取了必要且充分的保密措施，并严格控制本次交 易事项参与人员范围，尽可能地缩小知悉本次交易相关敏感信息的人员范围。 2、公司高度重视内幕信息管理，严格控制内幕信息知情人范围，及时记录 内幕信息知情人及筹划过程。 3、为保证本次交易的相关事宜不被泄露，公司与本次交易各方签署了《保 密协议》。公司及本次交易各方按照相关法律、法规和规范性文件的要求开展工 作，各方参与人员均严格遵守《保密协议》的规定。 4、公司严格按照深圳证券交易所要求制作内幕信息知情人登记表和交易进 程 ...

2024 年 9 月 10 日 特此说明。 海南双成药业股份有限公司董事会 根据《上市公司重大资产重组管理办法》第十四条的规定："上市公司在十 二个月内连续对同一或者相关资产进行购买、出售的，以其累计数分别计算相应 数额。已按照本办法的规定编制并披露重大资产重组报告书的资产交易行为，无 须纳入累计计算的范围。中国证监会对本办法第十三条第一款规定的重大资产重 组的累计期限和范围另有规定的，从其规定。交易标的资产属于同一交易方所有 或者控制，或者属于相同或者相近的业务范围，或者中国证监会认定的其他情形 下，可以认定为同一或者相关资产。" 经自查，在本次交易前十二个月内，公司未发生与本次交易相关的购买、出 售资产的交易行为，不存在需要纳入累计计算范围的情形。 海南双成药业股份有限公司董事会 关于本次交易前十二个月内购买、出售资产情况的说明 海南双成药业股份有限公司（以下简称"公司"）拟以发行股份及支付现金 的方式向 Hong Kong Aura Investment Co. Limited/香港奥拉投资有限公司、Win Aiming Limited/赢准有限公司等 25 名交易对方购买其持有的宁波奥拉半导体股 份有 ...

关于暂不召开股东大会的公告 证券代码：002693 证券简称：双成药业 公告编号：2024-062 海南双成药业股份有限公司 公司将在相关审计、评估工作完成后，再次召开董事会审议本次交易相关事 宜，并依法定程序召集股东大会并发布召开股东大会的通知，提请股东大会审议 本次交易的相关事宜。 特此公告。 海南双成药业股份有限公司董事会 2024 年 9 月 10 日 1 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 海南双成药业股份有限公司（以下简称"公司"）拟以发行股份及支付现金 的方式向 Hong Kong Aura Investment Co. Limited/香港奥拉投资有限公司、Win Aiming Limited/赢准有限公司等 25 名交易对方购买其持有的宁波奥拉半导体股 份有限公司 100%股份，并拟向不超过 35 名特定投资者发行股份募集配套资金 （以下简称"本次交易"）。 2024 年 9 月 10 日，公司召开第五届董事会第十五次会议，审议了《关于公 司发行股份及支付现金购买资产并募集配套资金暨关联交易方案的议案》等与本 次交易相关的议案， ...

1、擅自改变前次募集资金用途未作纠正，或者未经股东大会认可； 海南双成药业股份有限公司董事会 关于本次交易符合《上市公司证券发行注册管理办法》第十 一条规定的说明 海南双成药业股份有限公司（以下简称"公司"）拟以发行股份及支付现金 的方式向 Hong Kong Aura Investment Co. Limited/香港奥拉投资有限公司、Win Aiming Limited/赢准有限公司等 25 名交易对方购买其持有的宁波奥拉半导体股 份有限公司 100%股份，并向不超过 35 名特定投资者发行股份募集配套资金（以 下简称"本次交易"）。 经审慎判断，公司董事会认为，公司不存在《上市公司证券发行注册管理办 法》第十一条规定的不得向特定对象发行股票的如下情形： 2、最近一年财务报表的编制和披露在重大方面不符合企业会计准则或者相 关信息披露规则的规定；最近一年财务会计报告被出具否定意见或者无法表示意 见的审计报告；最近一年财务会计报告被出具保留意见的审计报告，且保留意见 所涉及事项对公司的重大不利影响尚未消除。本次发行涉及重大资产重组的除外； 6、最近三年存在严重损害投资者合法权益或者社会公共利益的重大违法行 为 ...

股票代码：002693 股票简称：双成药业 上市地点：深圳证券交易所 海南双成药业股份有限公司发行股份及支付现金 购买资产并募集配套资金暨关联交易预案（摘要） | 交易事项 | 交易对方名称 | | --- | --- | | 发行股份及支付现金购买资产 | Hong Kong Aura Investment Co. Limited、Win Aiming | | | 等 名交易对方 Limited 25 | | 募集配套资金 | 不超过三十五名特定投资者 | 签署日期：二〇二四年九月 海南双成药业股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易预案（摘要） 公司声明 本公司及全体董事、监事、高级管理人员保证本摘要内容不存在虚假记载、 误导性陈述或重大遗漏，并对其真实性、准确性和完整性承担法律责任。 截至本摘要签署日，与本次重组相关的审计、评估工作尚未完成，本公司及 全体董事、监事和高级管理人员保证本摘要所引用的相关数据的真实性和合理性。 本摘要所述事项并不代表中国证监会、深圳证券交易所对于本次重组相关事 项的实质性判断、确认或批准。本摘要所述本次重组相关事项的生效和完成尚需 有关审批机关的批准或 ...

关于公司遭受台风灾害影响的公告 证券代码：002693 证券简称：双成药业 公告编号：2024-058 海南双成药业股份有限公司 台风灾害发生后，公司立即启动灾害应急预案，组织力量全力进行抗灾减灾， 开展各种形式的生产自救及相应的补救措施，以最大限度降低台风灾害对公司经 营造成的损失。 截至目前，公司在本次台风灾害中损失主要集中在设备及系统工程部分受损， 初步估算损失金额约 520 余万元，但未发生人员伤亡。台风灾害过后，公司积极 投入复工复产工作中。截至本公告披露日，公司复工复产工作正在有序推进。目 前公司备货充足，此次灾害不会影响公司正常的供货和销售。 本次台风灾害对公司 2024 年度经营业绩产生的影响是公司财务部门初步测 算的结果，未经会计师事务所审计，具体损失以年度审计报告数据为准。敬请广 大投资者注意投资风险。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2024 年 9 月 6 日，海南遭受今年第 11 号超强台风"摩羯"袭击，海南双成 药业股份有公司（以下简称"公司"）厂区地址位于海南省海口市秀英区兴国路 16 号，受到了台风与暴雨叠加的灾 ...

证券代码：002693 证券简称：双成药业 公告编号：2024-057 海南双成药业股份有限公司 关于筹划重大资产重组暨关联交易进展并继续停牌的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 海南双成药业股份有限公司（以下简称"公司"）拟通过重大资产置换、发 行股份及支付现金的方式购买宁波奥拉半导体股份有限公司（以下简称"置入资 产""奥拉股份"）股权，同时拟向不超过 35 名特定投资者发行股份募集配套 资金（以下简称"本次交易"）。本次交易预计构成关联交易，构成重大资产重 组，不构成重组上市。 因有关事项尚存在不确定性，为了维护投资者利益，避免对公司证券交易造 成重大影响，根据深圳证券交易所的相关规定，经公司申请，公司股票（证券简 称：双成药业，证券代码：002693）自 2024 年 8 月 28 日（星期三）开市起开始 停牌，预计停牌时间不超过 5 个交易日，具体情况详见公司于 2024 年 8 月 28 日在《证券时报》、《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn） 披露的《关于筹划重大资产重组暨关联交易的停牌 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥94,892,601.28, a decrease of 31.74% compared to ¥139,013,360.10 in the same period last year[11]. - The net profit attributable to shareholders of the listed company was -¥16,946,164.02, representing a decline of 292.78% from ¥8,790,256.43 in the previous year[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥17,759,460.48, a decrease of 1,072.08% compared to -¥1,515,214.81 in the same period last year[11]. - The net cash flow from operating activities was -¥23,505,112.58, which is a decline of 19.29% from -¥19,703,531.96 in the previous year[11]. - The basic earnings per share were -¥0.0409, down 291.12% from ¥0.0214 in the same period last year[11]. - The total revenue for the industrial sector was approximately 72.74 million, a decrease of 43.94% compared to the same period last year[27]. - The company reported a net loss of CNY 14,905,033.04 from its subsidiary Ningbo Shuangcheng Pharmaceutical Co., Ltd., which had total assets of CNY 353,965,312.08[39]. - The company reported a significant increase in intangible assets to approximately 76.44 million, up from 52.81 million, due to successful R&D project approvals[30]. - The company reported a significant increase in long-term equity investments, reflecting a strategic focus on controlling and influencing key investments[152]. Assets and Liabilities - The total assets at the end of the reporting period were ¥819,840,725.21, an increase of 2.07% from ¥803,248,121.89 at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company were ¥454,768,795.84, a decrease of 3.55% from ¥471,485,892.58 at the end of the previous year[11]. - The company's total liabilities decreased from ¥139,000,000 to approximately ¥132,000,000, indicating a reduction of about 5%[88]. - The total liabilities increased from CNY 285,602,524.16 to CNY 326,185,889.42, representing a growth of approximately 14.2%[89]. - The company's total equity decreased from CNY 517,645,597.73 to CNY 493,654,835.79, a decline of approximately 4.6%[89]. - The company's retained earnings showed a negative balance, worsening from CNY -346,959,282.11 to CNY -363,905,446.13[89]. - The total liabilities and equity at the end of the reporting period were CNY 454,768,000, indicating a balanced financial position[103]. Research and Development - The company’s R&D investment increased by 28.96% to CNY 19.31 million, reflecting a commitment to innovation[24]. - The company has developed and registered nearly 10 peptide products, which are currently at various stages of approval and development, indicating a strong pipeline[20]. - The company has developed a new peptide synthesis technology aimed at reducing environmental pollution and production costs[23]. - The company’s growth strategy includes expanding its product line and enhancing its international market reach through ongoing research and development efforts[16]. Market and Product Information - The pharmaceutical manufacturing industry in China generated revenue of CNY 1,235.27 billion in the first half of 2024, a decrease of 0.9% year-on-year, while total profit increased by 0.7% to CNY 180.59 billion[15]. - The company’s main products include thymosin injection, somatostatin injection, and bivalirudin injection, with applications in chronic hepatitis B, severe acute gastrointestinal bleeding, and acute coronary syndrome[19]. - The company has successfully obtained marketing approvals from the US FDA and other regulatory bodies for several of its products, enhancing its market presence[18]. - The company achieved operating revenue of CNY 94.89 million, a decrease of 31.74% year-on-year, primarily due to the expansion of centralized procurement and a decline in drug prices[24]. Financial Assistance and Investments - The company provided a total financial assistance of up to RMB 15,840 million to its subsidiary Ningbo Shuangcheng, with a remaining balance of RMB 5,523.42 million as of June 30, 2024[60]. - The company approved a financial assistance of RMB 4,240 million to Ningbo Shuangcheng, with a borrowing period from September 1, 2024, to August 31, 2027[60]. - The company has guaranteed a total of RMB 16,500 million for Ningbo Shuangcheng, which accounts for 30.78% of the company's net assets[64]. - The company has a total of 82.13 million yuan in entrusted financial management, with overdue amounts of 24.99 million yuan and a provision for impairment of 40 million yuan[65]. Risk Management - The company faces various risks including industry policy changes, drug price reductions, and financial risks[2]. - The company acknowledges financial risks associated with expanding operations and international markets, particularly regarding foreign exchange fluctuations and increasing accounts receivable and inventory levels[42]. - The company has established a systematic pollution management system to mitigate environmental risks associated with its production processes[41]. - The company emphasizes the importance of product quality and has implemented strict quality management systems to mitigate quality risks, adhering to regulations such as CGMP and FDA standards[42]. Environmental and Social Responsibility - The company invested CNY 1.58 million in environmental protection facilities and daily expenses in the first half of 2024[51]. - The company paid CNY 814 in environmental protection tax during the reporting period[51]. - The company achieved a reduction of approximately 15% in natural gas consumption and a 50% reduction in nitrogen oxide emissions from its boilers after low-nitrogen modifications[51]. - The company has maintained compliance with environmental protection laws and regulations throughout its operations[51]. Shareholder Information - The total number of shares increased from 416,728,930 to 416,789,750 due to the exercise of stock options, with 60,820 options exercised during the reporting period[72]. - The total number of common shareholders at the end of the reporting period is 40,283[76]. - Hainan Shuangcheng Investment Co., Ltd. holds 32.75% of shares, totaling 136,516,546 shares[76]. - The company has not engaged in any repurchase transactions during the reporting period[78]. Corporate Governance - The company held its annual general meeting on May 22, 2024, with a participation rate of 50.16%[45]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[54]. - The company has not conducted any related party transactions during the reporting period[55]. - The company has not experienced any penalties or rectification issues during the reporting period[54]. Accounting and Financial Reporting - The company's financial statements are prepared in accordance with the relevant accounting standards and reflect its financial position accurately[116]. - The company recognizes deferred tax assets related to temporary differences if new information indicates realizable economic benefits[124]. - The company applies specific methods for translating foreign financial statements, including adjustments for hyperinflationary economies[131]. - The company recognizes impairment losses when the recoverable amount of an asset is less than its carrying amount, with the recoverable amount determined based on fair value or present value of future cash flows[169].